About: http://data.cimple.eu/news-article/afd2514395383548a1a5e89000ef1132d690169cbba6d35393de395e

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/afd2514395383548a1a5e89000ef1132d690169cbba6d35393de395e Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US drugmaker Eli Lilly's combination of two synthetic antibodies reduced hospitalizations and deaths in high-risk patients recently diagnosed with Covid-19 by 87 percent in trials, the company said Wednesday. The results come from a Phase 3 clinical trial of 769 people aged 12 and over with mild-to-moderate Covid-19, who were considered high-risk because of their age or underlying conditions. Among them, 511 received the combination treatment, which is authorized for emergency use in the United States, and 258 received a placebo. There were four hospitalizations and no deaths in the treatment group, while four people died in the placebo group and 11 were hospitalized. This represented a statistically significant risk reduction of 87 percent. The new results add to previous data reported by the company in January which used different dosing levels for the two antibodies and also showed a drastic risk reduction. The new results came with 700 mg of the antibody bamlanivimab and 1400 mg of etesevimab while the previously reported data used a combination of 2800 mg of each. "The consistent results observed in multiple cohorts of this trial over several months, even as new strains of COVID-19 have emerged, indicate bamlanivimab with etesevimab maintains its effects against a range of variants," said Daniel Skovronsky, the company's chief scientific officer. Monoclonal antibodies are lab-made versions of the body's natural infection-fighting defenses. Our bodies develop these proteins in response to pathogens, and vaccines train the immune systems to be prepared without encountering the live microbe itself. Giving people ready-made antibodies can help those who are at high risk of severe disease because of weak immunity or underlying conditions. But their uptake has been limited by factors including a lack of patient interest, and not enough staffing and places inside hospitals to administer them. It can also be challenging to identify candidates who are at high risk but haven't yet progressed to severe Covid. Serious allergic reactions have been observed in some people who were given the intravenously infused therapy. ia/bgs
schema:headline	Drugmaker Lilly says Covid treatment slashed hospitalization and deaths
schema:mentions	Eli Lilly and Company Intravenous therapy Clinical trial Placebo Antibody Allergy Ia (cuneiform) Immune system Coronavirus disease United States Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Microorganism Monoclonal antibody Progressed (EP)
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-03-10 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	85 (xsd:integer)
http://data.cimple...romotesConspiracy	suppressed cures conspiracy theory

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software